In clinical trials, for-profit review boards are taking over for hospitals. Should they?
By Sheila Kaplan,
STAT
| 07. 06. 2016
For years, ethicist Arthur Caplan warned medical researchers that paying businesses to evaluate their clinical trials was a bad idea.
He condemned trials that didn’t rely on hospital or academic review boards — long the gold standard in science — and argued that for-profit review boards were out to make a buck, not protect patients.
Today, Caplan sits on the advisory board of WIRB-Copernicus Group, the largest commercial institutional review board, or IRB, in the country.
He says he had no choice.
Continue reading on STAT
Image via Flickr/AJC
Related Articles
By Riley Beggin and Jeff Stein, The Washington Post | 08.03.2025
The White House does not plan to require health insurers to provide coverage for in vitro fertilization services, two people with knowledge of internal discussions said, even though the idea was one of President Donald Trump’s key campaign pledges.
Last...
By Sayantani DasGupta, MedPage Today | 08.05.2025
It's just a jeans ad.
It's not that deep.
It's just social media outrage.
Should physicians care about the recent American Eagle "Sydney Sweeney Has Good Genes Jeans" controversy? What, if anything, does the provocative campaign have to...
By Editors, Nature | 08.15.2025
A technology that played a key part in saving millions of lives during the COVID-19 pandemic1 should be feted to the skies. Instead, US health secretary Robert F. Kennedy Jr announced last week that the US federal government is...
By Staff, National Women's Law Center | 08.13.2025
INTRODUCTION
Baby bonuses. Motherhood medals. Fertility tracking. You may have heard of these policy proposals as solutions from the Trump administration to help encourage women to have more children.
Besides falling short of ensuring that people have what they need...
